Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.

Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ, Prieto JC.

Mol Cell Endocrinol. 2009 Apr 10;302(1):41-8. doi: 10.1016/j.mce.2008.11.024. Epub 2008 Dec 3.

PMID:
19101605
2.

Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.

Sotomayor S, Carmena MJ, Schally AV, Varga JL, Sánchez-Chapado M, Prieto JC, Bajo AM.

Int J Oncol. 2007 Nov;31(5):1223-30.

PMID:
17912451
3.

RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.

Valdehita A, Carmena MJ, Bajo AM, Prieto JC.

Mol Cell Endocrinol. 2012 Jan 2;348(1):241-6. doi: 10.1016/j.mce.2011.08.031. Epub 2011 Aug 27.

PMID:
21896307
4.

Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells.

Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM.

Regul Pept. 2007 Dec 4;144(1-3):101-8. Epub 2007 Jun 28.

PMID:
17683807
5.

Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.

Fink-Retter A, Gschwantler-Kaulich D, Hudelist G, Mueller R, Kubista E, Czerwenka K, Singer CF.

Oncol Rep. 2007 Aug;18(2):299-304.

PMID:
17611648
6.

Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.

Fernández-Martínez AB, Collado B, Bajo AM, Sánchez-Chapado M, Prieto JC, Carmena MJ.

Mol Cell Endocrinol. 2007 May 30;270(1-2):8-16. Epub 2007 Jan 21.

PMID:
17434257
7.

Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer.

Valdehita A, Bajo AM, Fernández-Martínez AB, Arenas MI, Vacas E, Valenzuela P, Ruíz-Villaespesa A, Prieto JC, Carmena MJ.

Peptides. 2010 Nov;31(11):2035-45. doi: 10.1016/j.peptides.2010.07.024. Epub 2010 Aug 5.

PMID:
20691743
8.

TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.

Helms MW, Kemming D, Contag CH, Pospisil H, Bartkowiak K, Wang A, Chang SY, Buerger H, Brandt BH.

Cancer Res. 2009 Jun 15;69(12):5049-56. doi: 10.1158/0008-5472.CAN-08-4154. Epub 2009 Jun 2.

9.

Leptin augments proliferation of breast cancer cells via transactivation of HER2.

Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H.

J Surg Res. 2008 Sep;149(1):9-14. doi: 10.1016/j.jss.2007.10.012. Epub 2007 Nov 26.

PMID:
18262553
10.

Lysophospholipids transactivate HER2/neu (erbB-2) in human gastric cancer cells.

Shida D, Kitayama J, Yamaguchi H, Yamashita H, Mori K, Watanabe T, Nagawa H.

Biochem Biophys Res Commun. 2005 Feb 18;327(3):907-14.

PMID:
15649431
11.

Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells.

Watt HL, Kharmate GD, Kumar U.

Cell Signal. 2009 Mar;21(3):428-39. doi: 10.1016/j.cellsig.2008.11.012. Epub 2008 Dec 3.

PMID:
19070659
12.
13.

Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells.

Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM.

Exp Cell Res. 2008 Oct 1;314(16):2907-18. doi: 10.1016/j.yexcr.2008.07.013. Epub 2008 Jul 25.

PMID:
18687326
14.

Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.

Vazquez-Martin A, Colomer R, Menendez JA.

Eur J Cancer. 2007 May;43(7):1117-24. Epub 2007 Mar 26.

PMID:
17379503
15.

The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation.

Garcia-Recio S, Pastor-Arroyo EM, Marín-Aguilera M, Almendro V, Gascón P.

PLoS One. 2015 Jun 26;10(6):e0129661. doi: 10.1371/journal.pone.0129661. eCollection 2015.

16.

Epidermal growth factor promotes epidermal growth factor receptor nuclear accumulation by a pathway dependent on cytoskeleton integrity in human breast cancer cells.

Cortes-Reynosa P, Robledo T, Salazar EP.

Arch Med Res. 2009 Jul;40(5):331-8. doi: 10.1016/j.arcmed.2009.06.007.

PMID:
19766894
17.

Lead acetate induces EGFR activation upstream of SFK and PKCalpha linkage to the Ras/Raf-1/ERK signaling.

Wang CY, Wang YT, Tzeng DW, Yang JL.

Toxicol Appl Pharmacol. 2009 Mar 1;235(2):244-52. doi: 10.1016/j.taap.2008.12.007. Epub 2008 Dec 24.

PMID:
19133285
18.

EGFR-dependent migration of glial cells is mediated by reorganisation of N-cadherin.

Rappl A, Piontek G, Schlegel J.

J Cell Sci. 2008 Dec 15;121(Pt 24):4089-97. doi: 10.1242/jcs.027995. Epub 2008 Nov 25.

19.

A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer.

Eladdadi A, Isaacson D.

Bull Math Biol. 2008 Aug;70(6):1707-29. doi: 10.1007/s11538-008-9315-4. Epub 2008 Jul 22.

PMID:
18648887
20.
Items per page

Supplemental Content

Write to the Help Desk